About Idenix Pharmaceuticals (NASDAQ:IDIX)
Idenix Pharmaceuticals, Inc. (Idenix) is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France. As of December 31, 2012, the Company's primary research and development focused on the treatment of patients with hepatitis C virus (HCV). In June 2012, the Company completed a three-day proof-of-concept study designed to evaluate 64 treatment-naive HCV genotype 1, 2, 3 or 4-infected patients. In July 2012, the FDA granted Fast Track designation for IDX719. The Company, as of December 31, 2012, was developing nucleotide polymerase inhibitors and NS 5A inhibitors to inhibits HCV replication, which include nucleoside/nucleotide polymerase inhibitors and NS5A Inhibitors. On January 25, 2013, the Company entered into a non-exclusive collaboration agreement with Janssen Pharmaceuticals, Inc for the clinical evaluation of all oral DAA HCV combination therapies.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on EquityN/A
Return on AssetsN/A
Idenix Pharmaceuticals (NASDAQ:IDIX) Frequently Asked Questions
What is Idenix Pharmaceuticals' stock symbol?
Idenix Pharmaceuticals trades on the NASDAQ under the ticker symbol "IDIX."
Who are some of Idenix Pharmaceuticals' key competitors?
Some companies that are related to Idenix Pharmaceuticals include CSL (CSL), Grifols SA, Barcelona (GRFS), Jazz Pharmaceuticals (JAZZ), Sirtex Medical (SRX), ProMetic Life Sciences (PLI), Theratechnologies (TH), Organigram (OGI), Mirati Therapeutics (MRTX), SIGA Technologies (SIGA), XOMA (XOMA), VBI Vaccines (VBIV), Osiris Therapeutics (OSIR), Anavex Life Sciences (AVXL), Trillium Therapeutics (TRIL), ContraFect (CFRX), Aevi Genomic Medicine (GNMX), Concordia International (CXR) and Sevion Therapeutics (SVON).
How do I buy Idenix Pharmaceuticals stock?
Shares of Idenix Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How can I contact Idenix Pharmaceuticals?
Idenix Pharmaceuticals' mailing address is 320 Bent St, CAMBRIDGE, MA 02141-2025, United States. The biopharmaceutical company can be reached via phone at +1-617-9959800.
MarketBeat Community Rating for Idenix Pharmaceuticals (IDIX)MarketBeat's community ratings are surveys of what our community members think about Idenix Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Idenix Pharmaceuticals (NASDAQ:IDIX) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Idenix Pharmaceuticals (NASDAQ:IDIX) Earnings History and Estimates Chart
Idenix Pharmaceuticals (NASDAQ IDIX) Earnings History by Quarter
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/1/2014||Q114||($0.19)||($0.24)||$0.22 million||($3.01) million||View||N/A|
|2/27/2014||Q413||($0.22)||($0.21)||$0.15 million||$0.50 million||View||N/A|
|2/25/2013||Q412||($0.17)||($0.17)||$0.74 million||$0.33 million||View||N/A|
|11/1/2012||Q312||($0.17)||$0.03||$2.60 million||$32.30 million||View||N/A|
Idenix Pharmaceuticals (NASDAQ:IDIX) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Idenix Pharmaceuticals (NASDAQ:IDIX)
No dividend announcements for this company have been tracked by MarketBeat.com
Idenix Pharmaceuticals (NASDAQ IDIX) Insider Trading and Institutional Ownership History
Idenix Pharmaceuticals (NASDAQ IDIX) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|1/31/2014||Baupost Group Llc/Ma||major shareholder||Buy||16,420,241||$6.50||$106,731,566.50|| |
Idenix Pharmaceuticals (NASDAQ IDIX) News Headlines
Idenix Pharmaceuticals (NASDAQ:IDIX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Idenix Pharmaceuticals (NASDAQ:IDIX) Income Statement, Balance Sheet and Cash Flow Statement
Idenix Pharmaceuticals (NASDAQ IDIX) Stock Chart for Thursday, December, 14, 2017